Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Roche Alzheimer's drug fails, joining long list of trial flops

ZURICH (Reuters) - An experimental Alzheimer's drug from Roche ROG.S and AC Immune ACIU.O failed to slow cognitive and functional decline in a trial, the Swiss companies said on Wednesday, in a fresh setback to efforts to fight the fatal dementia-causing disease.

AC Immune boss Andrea Pfeifer described the results of the trial of semorinemab as “surprising and disappointing”.

The drug targets “tau” proteins believed to play a role in Alzheimer’s and offers an alternative to treatments aiming to fight amyloid beta peptides in the brain.

The outcome of the Phase 2 trial - in patients with an early stage of Alzheimer’s - means the failure rate for drugs aiming to fight the brain-wasting illness, which afflicts tens of millions of people worldwide, remains at nearly 100%.

“We believe the full data analysis of this first-of-its-kind study will yield information about this promising target that will advance our understanding and inform future efforts,” Pfeifer said.

So far, Alzheimer's drugs have nearly always stumbled in trials, though the U.S. Food and Drug Administration is now reviewing experimental treatment aducanumab from Biogen BIIB.O and Japan's Eisai 4523.T, marking the first Alzheimer's drug application in 17 years to be reviewed by the agency.

Aducanumab targets amyloid beta peptides, but nearly all similar drugs have failed, so far, including prospective medicines from Roche and AC Immune. Consequently, the companies were hoping anti-tau medicines like semorinemab would yield better results and said this result was a disappointment.

“We believe these data will contribute to the scientific understanding of the role of tau in this complex and difficult-to-treat disease,” said Rachelle Doody, head of Roche’s neurodegeneration operation.

Roche and AC Immune have other anti-tau medicines in development, along with many other companies, including Eli Lilly LLY.N, Biogen and Johnson & Johnson JNJ.N.

SEPTEMBER 23, 2020


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies